Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)

NCT06699836 is registered in ClinicalTrials.gov with CytoDyn, Inc. as lead sponsor.

NCT NCT06699836
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06699836 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Two Study Evaluating Two Doses of Leronlimab (PRO 140) In Combination With Trifluridine + Tipiracil (TAS-102) + Bevacizumab in Participants With Microsatellite Stable (MSS), Relapsed Refractory Metastatic Colorectal Cancer (mCRC)
Lead sponsor
CytoDyn, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 16, 2025
Completion date
March 31, 2028
Enrollment
66 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal cancer (mcrc)